Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead drug candidate Lucid-MS, a potential treatment for multiple sclerosis, toward a Phase 2 clinical trial, while simultaneously generating revenue from its commercially available product unbuzzd, according to Executive Co-Chairman and Co-Founder Anthony Durkacz in a recent BioMedWire Podcast.
Durkacz explained that Lucid-MS aims to address mobility damage associated with multiple sclerosis, a neurodegenerative condition affecting millions worldwide. The company has filed an investigational new drug application for a Phase 2 trial, which would mark the first administration of Lucid-MS to human MS patients. This milestone is critical for Quantum BioPharma’s pipeline, as Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying mechanism of multiple sclerosis, making Lucid-MS a promising candidate for disease modification. The company’s wholly owned subsidiary, Lucid Psycheceuticals Inc., is leading the research and development efforts. More details on the company’s strategy are available in the full podcast here.
In addition to its clinical-stage assets, Quantum BioPharma has commercialized unbuzzd, a product designed to accelerate alcohol metabolism. Quantum BioPharma invented unbuzzd and spun out its over-the-counter version to Unbuzzd Wellness Inc., a company led by industry veterans. Quantum BioPharma retains a 19.84% ownership stake in UWI as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. The company also retains 100% of rights to develop pharmaceutical and medical uses of the product. This dual strategy allows Quantum BioPharma to generate near-term revenue while pursuing long-term pharmaceutical development. The unbuzzd product is available through unbuzzd.com.
Quantum BioPharma’s approach reflects a broader trend in the biopharmaceutical industry: combining clinical-stage drug development with commercial products to create a diversified business model. For investors, the progression of Lucid-MS into human trials represents a significant de-risking event, while unbuzzd provides a tangible revenue stream that can support ongoing research. The company’s focus on neurodegenerative, metabolic, and alcohol-misuse conditions positions it across multiple therapeutic areas with high unmet need. As Durkacz emphasized, the strategy is to leverage both short-term commercial opportunities and long-term clinical value. For more information on the company and its latest updates, visit the newsroom at https://ibn.fm/QNTM.
